299 related articles for article (PubMed ID: 38090060)
1. Progress in phase III clinical trials of molecular targeted therapy and immunotherapy for glioblastoma.
Wang Y; Li S; Peng Y; Ma W; Wang Y; Li W
Cancer Innov; 2023 Apr; 2(2):114-130. PubMed ID: 38090060
[TBL] [Abstract][Full Text] [Related]
2. The need for paradigm shift: prognostic significance and implications of standard therapy-related systemic immunosuppression in glioblastoma for immunotherapy and oncolytic virotherapy.
Stepanenko AA; Sosnovtseva AO; Valikhov MP; Chernysheva AA; Abramova OV; Naumenko VA; Chekhonin VP
Front Immunol; 2024; 15():1326757. PubMed ID: 38390330
[TBL] [Abstract][Full Text] [Related]
3. Imposing Phase II and Phase III Clinical Trials of Targeted Drugs for Glioblastoma: Current Status and Progress.
Wang Y; Chen W; Shi Y; Yan C; Kong Z; Wang Y; Wang Y; Ma W
Front Oncol; 2021; 11():719623. PubMed ID: 34568049
[TBL] [Abstract][Full Text] [Related]
4. Topics in chemotherapy, molecular-targeted therapy, and immunotherapy for newly-diagnosed glioblastoma multiforme.
Okonogi N; Shirai K; Oike T; Murata K; Noda SE; Suzuki Y; Nakano T
Anticancer Res; 2015 Mar; 35(3):1229-35. PubMed ID: 25750269
[TBL] [Abstract][Full Text] [Related]
5. Current Immunotherapies for Glioblastoma Multiforme.
Huang B; Li X; Li Y; Zhang J; Zong Z; Zhang H
Front Immunol; 2020; 11():603911. PubMed ID: 33767690
[TBL] [Abstract][Full Text] [Related]
6. Glioblastoma Multiforme: The Latest Diagnostics and Treatment Techniques.
Czarnywojtek A; Borowska M; Dyrka K; Van Gool S; Sawicka-Gutaj N; Moskal J; Kościński J; Graczyk P; Hałas T; Lewandowska AM; Czepczyński R; Ruchała M
Pharmacology; 2023; 108(5):423-431. PubMed ID: 37459849
[TBL] [Abstract][Full Text] [Related]
7. Glioblastoma Immunotherapy: A Systematic Review of the Present Strategies and Prospects for Advancements.
Agosti E; Zeppieri M; De Maria L; Tedeschi C; Fontanella MM; Panciani PP; Ius T
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894718
[TBL] [Abstract][Full Text] [Related]
8. Emerging immunotherapies for glioblastoma.
Desai R; Suryadevara CM; Batich KA; Farber SH; Sanchez-Perez L; Sampson JH
Expert Opin Emerg Drugs; 2016 Jun; 21(2):133-45. PubMed ID: 27223671
[TBL] [Abstract][Full Text] [Related]
9. An Update on the Role of Immunotherapy and Vaccine Strategies for Primary Brain Tumors.
Neagu MR; Reardon DA
Curr Treat Options Oncol; 2015 Nov; 16(11):54. PubMed ID: 26454859
[TBL] [Abstract][Full Text] [Related]
10. Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme.
Polivka J; Polivka J; Holubec L; Kubikova T; Priban V; Hes O; Pivovarcikova K; Treskova I
Anticancer Res; 2017 Jan; 37(1):21-33. PubMed ID: 28011470
[TBL] [Abstract][Full Text] [Related]
11. Recent Advances in Oncolytic Virotherapy and Immunotherapy for Glioblastoma: A Glimmer of Hope in the Search for an Effective Therapy?
Stepanenko AA; Chekhonin VP
Cancers (Basel); 2018 Dec; 10(12):. PubMed ID: 30563098
[TBL] [Abstract][Full Text] [Related]
12. Combinatorial approaches to effective therapy in glioblastoma (GBM): Current status and what the future holds.
Asija S; Chatterjee A; Yadav S; Chekuri G; Karulkar A; Jaiswal AK; Goda JS; Purwar R
Int Rev Immunol; 2022; 41(6):582-605. PubMed ID: 35938932
[TBL] [Abstract][Full Text] [Related]
13. [What's next in glioblastoma treatment: Tumor-targeted or immune-targeted therapies?].
Schernberg A; Marabelle A; Massard C; Armand JP; Dumont S; Deutsch E; Dhermain F
Bull Cancer; 2016 May; 103(5):484-98. PubMed ID: 27032303
[TBL] [Abstract][Full Text] [Related]
14. A Characterization of Dendritic Cells and Their Role in Immunotherapy in Glioblastoma: From Preclinical Studies to Clinical Trials.
Srivastava S; Jackson C; Kim T; Choi J; Lim M
Cancers (Basel); 2019 Apr; 11(4):. PubMed ID: 30991681
[TBL] [Abstract][Full Text] [Related]
15. Tumor treating fields: a novel and effective therapy for glioblastoma: mechanism, efficacy, safety and future perspectives.
Zhu P; Zhu JJ
Chin Clin Oncol; 2017 Aug; 6(4):41. PubMed ID: 28841803
[TBL] [Abstract][Full Text] [Related]
16. The future of glioblastoma therapy: synergism of standard of care and immunotherapy.
Patel MA; Kim JE; Ruzevick J; Li G; Lim M
Cancers (Basel); 2014 Sep; 6(4):1953-85. PubMed ID: 25268164
[TBL] [Abstract][Full Text] [Related]
17. A randomized controlled phase II trial of vaccination with lysate-loaded, mature dendritic cells integrated into standard radiochemotherapy of newly diagnosed glioblastoma (GlioVax): study protocol for a randomized controlled trial.
Rapp M; Grauer OM; Kamp M; Sevens N; Zotz N; Sabel M; Sorg RV
Trials; 2018 May; 19(1):293. PubMed ID: 29801515
[TBL] [Abstract][Full Text] [Related]
18. Vaccination in the immunotherapy of glioblastoma.
Kong Z; Wang Y; Ma W
Hum Vaccin Immunother; 2018 Feb; 14(2):255-268. PubMed ID: 29087782
[TBL] [Abstract][Full Text] [Related]
19. Translational landscape of glioblastoma immunotherapy for physicians: guiding clinical practice with basic scientific evidence.
Kreatsoulas D; Bolyard C; Wu BX; Cam H; Giglio P; Li Z
J Hematol Oncol; 2022 Jun; 15(1):80. PubMed ID: 35690784
[TBL] [Abstract][Full Text] [Related]
20. Dendritic cell vaccines for glioblastoma fail to complete clinical translation: Bottlenecks and potential countermeasures.
Li L; Zhou J; Dong X; Liao Q; Zhou D; Zhou Y
Int Immunopharmacol; 2022 Aug; 109():108929. PubMed ID: 35700581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]